Holen Sie sich die Stockscreener-App
1.04
1.89%
-0.02
Handel nachbörslich:
.99
-0.05
-4.81%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.07
24-Stunden-Volumen:
258.09K
Relative Volume:
0.63
Marktkapitalisierung:
$19.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.56M
KGV:
-0.20
EPS:
-5.2
Netto-Cashflow:
$-19.35M
1W Leistung:
+0.97%
1M Leistung:
+25.59%
6M Leistung:
-62.86%
1J Leistung:
-76.36%
1-Tages-Spanne:
$0.99
$1.07
1-Wochen-Bereich:
$0.99
$1.09
52-Wochen-Spanne:
$0.62
$7.50
Biovie Inc Stock (BIVI) Company Profile
Firmenname
Biovie Inc
Sektor
Branche
Telefon
775-888-3162
Adresse
680 W NYE LANE, CARSON CITY
Vergleichen Sie BIVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.04 | 19.12M | 0 | -25.56M | -19.35M | -5.20 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Eingeleitet | B. Riley Securities | Buy |
Biovie Inc Aktie (BIVI) Neueste Nachrichten
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Lohud
Investors' Lawsuit Against BioVie Moves to Evidence Review — Here's How to Recover Losses - TradingView
Transcript : BioVie Inc.Special Call - marketscreener.com
BioVie (NASDAQ:BIVI) Trading 1.9% Higher – Time to Buy? - Defense World
FY2025 EPS Estimates for BioVie Raised by Analyst - Defense World
BioVie Inc. Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - marketscreener.com
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BI - GuruFocus
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BIVI Stock News - GuruFocus
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial - GlobeNewswire
New Long COVID Treatment Hope: BioVie Launches Phase 2 Trial for 20M+ US Patients with Brain Fog - Stock Titan
BioVie (BIVI) To Host Key Opinion Leader Event Discussing Parkin - GuruFocus
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of - GuruFocus
BioVie to host KOL event on Phase 2 study of bezisterim - TipRanks
BioVie Inc. to Host Virtual KOL Event Discussing Parkinson’s Disease and Update on Phase 2 SUNRISE-PD Trial for Bezisterim - Nasdaq
BioVie to Host Virtual KOL Event to Discuss the Phase 2 - GlobeNewswire
Biovie Inc. to Host Virtual Kol Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 - marketscreener.com
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
BIOVIE Earnings Results: $BIVI Reports Quarterly Earnings - Nasdaq
BIOVIE INC. SEC 10-Q Report - TradingView
Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
BioVie (BIVI) to Release Quarterly Earnings on Tuesday - Defense World
Investors who lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
BioVie Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsBIVI - ACCESS Newswire
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
Investors who lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024BIVI - ACCESS Newswire
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out - ACCESS Newswire
BioVie to Present Rationale and Design of Phase 2 - GlobeNewswire
BioVie (BIVI) Showcases Parkinson's Trial at Global Conference | BIVI Stock News - GuruFocus
Market Insights: BioVie Inc (BIVI)’s Notable Gain of 1.75, Closing at 1.16 - DWinneX
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025) - TradingView
BioVie (BIVI) Establishes Influential Corporate Advisory Board | - GuruFocus
BioVie assembles advisory board for neurodegenerative care By Investing.com - Investing.com Canada
BioVie (BIVI) Establishes Influential Corporate Advisory Board | BIVI Stock News - GuruFocus
BioVie assembles advisory board for neurodegenerative care - Investing.com
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth - The Manila Times
BioVie (BIVI) Advances Parkinson's Trial with Innovative Drug Be - GuruFocus
BioVie (BIVI) Advances Key Drug Treatments and Clinical Trials - GuruFocus
BioVie Unveils Corporate Advisory Board Featuring Neuralink - GlobeNewswire
BioVie Inc. Announces Formation of Corporate Advisory Board - marketscreener.com
BioVie (BIVI) Advances Parkinson's Trial with Innovative Drug Bezisterim - GuruFocus
Geode Capital Management LLC Buys 85,234 Shares of BioVie Inc. (NASDAQ:BIVI) - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BioVie Inc (BIVI) Stock: A Year of Highs and Lows - investchronicle.com
Shareholders That Lost Money on BioVie Inc.(BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Finanzdaten der Biovie Inc-Aktie (BIVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):